Efficacy, Satisfaction, and Compliance: Insights from 15 Years of Botulinum Toxin Use for Female Urgency Urinary Incontinence
Abstract
:1. Introduction
2. Results
3. Discussion
4. Conclusions
5. Materials and Methods
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Milsom, I.; Irwin, D.E. A Cross-Sectional, Population-Based, Multinational Study of the Prevalence of Overactive Bladder and Lower Urinary Tract Symptoms: Results from the EPIC Study. Eur. Urol. Suppl. 2007, 6, 4–9. [Google Scholar] [CrossRef]
- Partin, A.W.; Dmochowsky, R.R.; Kavoussi, L.R.; Peters, C.A. Campbell-Walsh-Wein Urology, 12th ed.; Elsevier: Philadelphia, PA, USA, 2020; pp. 2581–2586, 2592, 2638–2639, 2707–2709. [Google Scholar]
- Nambiar, A.K.; Arlandis, S.; Bø, K.; Cobussen-Boekhorst, H.; Costantini, E.; de Heide, M.; Farag, F.; Groen, J.; Karavitakis, M.; Lapitan, M.C.; et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. Eur. Urol. 2022, 82, 49–59. [Google Scholar] [CrossRef]
- Amundsen, C.L.; Komesu, Y.M.; Chermansky, C.; Gregory, W.T.; Myers, D.L.; Honeycutt, E.F.; Vasavada, S.P.; Nguyen, J.N.; Wilson, T.S.; Harvie, H.S.; et al. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. Eur. Urol. 2018, 74, 66–73. [Google Scholar] [CrossRef] [PubMed]
- Harvie, H.S.; Amundsen, C.L.; Neuwahl, S.J.; Honeycutt, A.A.; Lukacz, E.S.; Sung, V.W.; Rogers, R.G.; Ellington, D.; Ferrando, C.A.; Chermansky, C.J.; et al. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial. J. Urol. 2020, 203, 969–977. [Google Scholar] [CrossRef]
- Lin, Y.H.; Chiang, B.J.; Liao, C.H. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders. Toxin 2020, 12, 129. [Google Scholar] [CrossRef] [PubMed]
- Cruz, F. Targets for botulinum toxin in the lower urinary tract. Neurourol. Urodyn. 2014, 33, 31–38. [Google Scholar] [CrossRef] [PubMed]
- Dolly, J.O.; Lawrence, G.W. Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A. Neurourol. Urodyn. 2014, 33 (Suppl. S3), S14–S20. [Google Scholar] [CrossRef]
- Apostolidis, A.; Jacques, T.S.; Freeman, A.; Kalsi, V.; Popat, R.; Gonzales, G.; Datta, S.N.; Ghazi-Noori, S.; Elneil, S.; Dasgupta, P.; et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur. Urol. 2008, 53, 1245–1253. [Google Scholar] [CrossRef] [PubMed]
- Brin, M.F.; James, C.; Maltman, J. Botulinum toxin type A products are not interchangeable: A review of the evidence. Biologics 2014, 8, 227–241. [Google Scholar] [CrossRef]
- Nitti, V.W.; Dmochowski, R.; Herschorn, S.; Sand, P.; Thompson, C.; Nardo, C.; Yan, X.; Haag-Molkenteller, C. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial. J. Urol. 2013, 189, 2186–2193. [Google Scholar] [CrossRef] [PubMed]
- Avallone, M.A.; Sack, B.S.; El-Arabi, A.; Guralnick, M.L.; O’Connor, R.C. Less is more-A pilot study evaluating one to three intradetrusor sites for injection of onabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity. Neurourol. Urodyn. 2017, 36, 1104–1107. [Google Scholar] [CrossRef] [PubMed]
- Martínez-Cuenca, E.; Bonillo, M.A.; Morán, E.; Broseta, E.; Arlandis, S. Onabotulinumtoxin re-injection for refractory detrusor overactivity using 3-4 injection sites: Results of a pilot study. Urology 2020, 137, 50–54. [Google Scholar] [CrossRef] [PubMed]
- Jo, J.K.; Kim, K.N.; Kim, D.W.; Kim, Y.T.; Kim, J.Y.; Kim, J.Y. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: A systematic review and meta-analysis. World J. Urol. 2018, 36, 305–317. [Google Scholar] [CrossRef] [PubMed]
- Manecksha, R.P.; Cullen, I.M.; Ahmad, S.; McNeill, G.; Flynn, R.; McDermott, T.E.; Grainger, R.; Thornhill, J.A. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur. Urol. 2012, 61, 928–935. [Google Scholar] [CrossRef] [PubMed]
- DiCarlo-Meacham, A.M.; Dengler, K.L.; Welch, E.K.; Brooks, D.I.; Gruber, D.D.; Osborn, D.J.; Scarlotta, L.; Vaccaro, C.M. Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder. Neurourol. Urodyn. 2023, 42, 366–374. [Google Scholar] [CrossRef] [PubMed]
- MacDiarmid, S.; Glazier, D.B.; McCrery, R.J.; Kennelly, M.J.; Nelson, M.; Ifantides, K.B.; McCammon, K.A. Efficacy and safety of an alternative onabotulinumtoxinA injection paradigm for refractory overactive bladder. Neurourol. Urodyn. 2024, 43, 31–43. [Google Scholar] [CrossRef]
- Kelsey, E.; Wynn, J.; Holmes, A.; McLeod, K. Anatomical location and number of injection sites of intravesical OnabotulinumtoxinA for females with refractory idiopathic overactive bladder: A scoping review. Neurourol. Urodyn. 2024, 43, 553–564. [Google Scholar] [CrossRef] [PubMed]
- Chapple, C.R.; Sievert, K.D.; MacDiarmid, S.; Khullar, V.; Radziszweski, P.; Nardo, C.; Thompson, C.; Zhou, J.; Haag-Molkenteller, C. OnabotulinomtoxiA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial. Eur. Urol. 2013, 64, 249–256. [Google Scholar] [CrossRef]
- Hsieh, P.F.; Chiu, H.C.; Chen, K.C.; Chang, C.H.; Chou, E.C. Botulinum toxin A for the Treatment of Overactive Bladder. Toxins 2016, 8, 59. [Google Scholar] [CrossRef] [PubMed]
- Irwin, D.E.; Kopp, Z.S.; Agatep, B.; Milsom, I.; Abrams, P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011, 108, 1132–1138. [Google Scholar] [CrossRef] [PubMed]
- Manso, M.; Botelho, F.; Bulhões, C.; Cruz, F.; Pacheco-Figueiredo, L. Self-reported urinary incontinence in women is higher with increased age, lower educational level, lower income, number of comorbidities, and impairment of mental health. Results of a large, population-based, national survey in Portugal. World J. Urol. 2023, 41, 3657–3662. [Google Scholar] [CrossRef] [PubMed]
- Cox, L.; Cameron, A.P. OnabotulinumtoxinA for the treatment of overactive bladder. Res. Rep. Urol. 2014, 6, 79–89. [Google Scholar] [CrossRef] [PubMed]
- Miotla, P.; Futyma, K.; Cartwright, R.; Bogusiewicz, M.; Skorupska, K.; Markut-Miotla, E.; Rechberger, T. Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery. Int. Urogynecol. J. 2016, 27, 393–398. [Google Scholar] [CrossRef] [PubMed]
- Chai, T.C.; Richter, H.E.; Moalli, P.; Keay, S.; Biggio, J.; Zong, W.; Curto, T.; Kim, H.Y.; Stoddard, A.M.; Kusek, J.W. Inflammatory and tissue remodeling urinary biomarkers before and after mid urethral sling surgery for stress urinary incontinence. J. Urol. 2014, 191, 703–709. [Google Scholar] [CrossRef]
- Antunes-Lopes, T.; Coelho, A.; Pinto, R.; Barros, S.C.; Cruz, C.; Cruz, F.; Silva, C.M. Urinary Neurotrophin Levels Increase in Women With Stress Urinary Incontinence After a Midurethral Sling Procedure. Urology 2017, 99, 49–56. [Google Scholar] [CrossRef]
- Kalsi, V.; Apostolidis, A.; Gonzales, G.; Elneil, S.; Dasgupta, P.; Fowler, C. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur. Urol. 2008, 54, 181–187. [Google Scholar] [CrossRef] [PubMed]
- Sahai, A.; Dowson, C.; Khan, M.; Dasgupta, P.; GKT Botulinum Study Group. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010, 75, 552–558. [Google Scholar] [CrossRef]
- Coelho, A.; Cruz, F.; Cruz, C.D.; Avelino, A. Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur. Urol. 2012, 61, 1178–1184. [Google Scholar] [CrossRef]
- Chuang, Y.C.; Kuo, H.C. A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxinA for interstitial cystitis/bladder pain syndrome. J. Urol. 2017, 198, 376–382. [Google Scholar] [CrossRef] [PubMed]
- Rappaport, Y.H.; Zisman, A.; Jeshurun-Gutshtat, M.; Gerassi, T.; Hakim, G.; Vinshtok, Y.; Stav, K. Safety and feasibility of intravesical instillation of botulinum toxin-A in hydrogel-based slow-release delivery system in patients with interstitial cystitis-bladder pain syndrome: A pilot study. Urology 2018, 114, 60–65. [Google Scholar] [CrossRef] [PubMed]
- Nageib, M.; El-Hefnawy, A.S.; Zahran, M.H.; El-Tabey, N.A.; Sheir, K.Z.; Shokeir, A.A. Delivery of intravesical botulinum toxin A using low-energy shockwaves in the treatment of overactive bladder: A preliminary clinical study. Arab. J. Urol. 2019, 17, 216–220. [Google Scholar] [CrossRef] [PubMed]
- Kajbafzadeh, A.M.; Montaser-Kouhsari, L.; Ahmadi, H.; Sotoudeh, M. Intravesical electromotive botulinum toxin type A administration: Part I—Experimental study. Urology 2011, 77, 1460–1464. [Google Scholar] [CrossRef] [PubMed]
- Pereira e Silva, R.; Ponte, C.; Lopes, F.; Palma Dos Reis, J. Alkalinized lidocaine solution as a first-line local anesthesia protocol for intradetrusor injection of onabotulinum toxin A: Results from a double-blinded randomized controlled trial. Neurourol. Urodyn. 2020, 39, 2471–2479. [Google Scholar] [CrossRef]
- Coupland, A.C.; Hill, T.; Dening, T.; Morriss, R.; Moore, M.; Hippisley-Cox, J. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Intern. Med. 2019, 179, 1084–1093. [Google Scholar] [CrossRef] [PubMed]
- Drake, M.J.; Nitti, V.W.; Ginsberg, D.A.; Brucker, B.M.; Hepp, Z.; McCool, R.; Glanville, J.M.; Fleetwood, K.; James, D.; Chapple, C.R. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: A systematic review and network meta-analysis. BJU Int. 2017, 120, 611–622. [Google Scholar] [CrossRef] [PubMed]
- Kuo, H. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin A injection for idiopathic detrusor overactivity. Neurourol. Urodyn. 2011, 30, 1497–1502. [Google Scholar] [CrossRef] [PubMed]
- Hendrickson, W.K.; Xie, G.; Rahn, D.D.; Amundsen, C.L.; Hokanson, J.A.; Bradley, M.; Smith, A.L.; Sung, V.W.; Visco, A.G.; Luo, S.; et al. Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women. Neurourol. Urodyn. 2022, 41, 432–447. [Google Scholar] [CrossRef]
Number of Treatments | Number of Patients (%) |
---|---|
0 | 146 (39.7) |
1 | 114 (30.9) |
2 | 61 (16.6) |
3 | 24 (6.5) |
4 | 8 (2.2) |
5 | 7 (1.9) |
6 | 6 (1.6) |
7 | 1 (0.3) |
8 | 1 (0.3) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Manso, M.; Soares, J.D.; Henriques, M.; Botelho, F.; Silva, C.; Cruz, F. Efficacy, Satisfaction, and Compliance: Insights from 15 Years of Botulinum Toxin Use for Female Urgency Urinary Incontinence. Toxins 2024, 16, 332. https://doi.org/10.3390/toxins16080332
Manso M, Soares JD, Henriques M, Botelho F, Silva C, Cruz F. Efficacy, Satisfaction, and Compliance: Insights from 15 Years of Botulinum Toxin Use for Female Urgency Urinary Incontinence. Toxins. 2024; 16(8):332. https://doi.org/10.3390/toxins16080332
Chicago/Turabian StyleManso, Margarida, João Diogo Soares, Margarida Henriques, Francisco Botelho, Carlos Silva, and Francisco Cruz. 2024. "Efficacy, Satisfaction, and Compliance: Insights from 15 Years of Botulinum Toxin Use for Female Urgency Urinary Incontinence" Toxins 16, no. 8: 332. https://doi.org/10.3390/toxins16080332